Blueprint Medicines Corp 2024年度报告

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesNoIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YesNo Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of itsinternal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountingfirm that prepared or issued its audit report. YesNo If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrantincluded in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNo As of June 30, 2024, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, basedon the last reported sales price for the registrant’s common stock, par value $0.001 per share, on the Nasdaq Global Select Market on such date,was approximately $6,747,459,120. Number of shares of the registrant’s common stock, par value $0.001 per share, outstanding on February 11, 2025: 63,906,011 DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders, which the registrant intends to file withthe Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year endedDecember 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K. TABLE OF CONTENTS PART I Business5Risk Factors39Unresolved Staff Comments89Cybersecurity89Properties90Legal Proceedings90Mine Safety Disclosures90PART IIMarket for Registrant’s Common Equity, Related Stockholder Mattersand Issuer Purchases of Equity Securities91Reserved92Management’s Discussion and Analysis of Financial Condition andResults of Operations92Quantitative and Qualitative Disclosures About Market Risk108Financial Statements and Supplementary Data109Change in and Disagreements with Accountants on Accounting andFinancial Disclosure.109Controls and Procedures109Other Information111Disclosure Regarding Foreign Jurisdictions that Prevent Inspections112PART IIIDirectors, Executive Officers and Corporate Governance112Executive Compensation112Security Ownership of Certain Beneficial Owners and Management andRelated Stockholder Matters112Certain Relationships and Related Transactions, and DirectorIndependence112Principal Accounting Fees and Services112PART IVExhibits and Financial Statement Schedules113Form 10-K Summary122 Item 1.Item1A.Item 1B.Item 1C.Item 2.Item 3.Item 4. Item 5. Item 6.Item 7. Item 9A.Item 9B.Item 9C. Item 13. Item 14. Table of Contents Unless otherwise stated, all references to “us,” “our,” “Blueprint,” “Blueprint Medicines,” “we,” the“Company” and similar designations in this Annual Report on Form 10-K refer to Blueprint Medicines Corporationand its consolidated subsidiaries. Blueprint Medicines, AYVAKIT®, AYVAKYT® and associated logos aretrademarks of Blueprint Medicines Corporation. Other brands, names and trademarks contained in this AnnualReport on Form 10-K are t